Human papilloma virus vaccination and dysautonomia: Considerations for autoantibody evaluation and HLA typing

Vaccine

Volumn 34, Issue 38, 2016, Pages 4468-

  Hendrickson, Jeanne E ^a   Tormey, Christopher A ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Autoimmunity; Complex regional pain syndrome; Dysautonomia; HPV; Human papilloma virus vaccination

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; AUTOANTIBODY; BETA 2 ADRENERGIC RECEPTOR; IMMUNOGLOBULIN; MUSCARINIC M2 RECEPTOR; MYCOPHENOLIC ACID; NICOTINIC ACETYLCHOLINE GANGLIONIC RECEPTOR; PROTEIN; RITUXIMAB; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

COMPLEX REGIONAL PAIN SYNDROME; DYSAUTONOMIA; EPSTEIN BARR VIRUS INFECTION; FAINTNESS; FATIGUE; GASTROINTESTINAL MOTILITY DISORDER; HLA TYPING; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; HYPOTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; KNEE PAIN; LETTER; NEUROPATHY; PLASMA EXCHANGE; POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME; PRESYNCOPE; PRIORITY JOURNAL; REHYDRATION; RHEUMATIC DISEASE; SLEEP DISORDER; STOMACH PAIN; VACCINATION; HISTOCOMPATIBILITY TEST; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; UTERINE CERVIX TUMOR;

AUTOANTIBODIES; HISTOCOMPATIBILITY TESTING; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRIMARY DYSAUTONOMIAS; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84996490483     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.05.029     Document Type: Letter

References (3)

1. [1] Brinth, L.S., Pors, K., Theibel, A.C., Mehlsen, J., Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus. Vaccine 33 (2015), 2602–2605.
2. [2] Hendrickson, J.E., Hendrickson, E.T., Gehrie, E.A., Sidhu, D., Wallukat, G., Schimke, I., et al. Complex regional pain syndrome and dysautonomia in a 14-year-old girl responsive to therapeutic plasma exchange. J Clin Apheresis, 2015, 10.1002/jca.21407.
3. [3] European Medicines Agency, Pharmovigilance Risk Assessment Committee, Human Papillomavirus (HPV) Vaccines. 2015 EMA/762033/2015Nov 11.